JP5986072B2 - 組成物 - Google Patents

組成物 Download PDF

Info

Publication number
JP5986072B2
JP5986072B2 JP2013513755A JP2013513755A JP5986072B2 JP 5986072 B2 JP5986072 B2 JP 5986072B2 JP 2013513755 A JP2013513755 A JP 2013513755A JP 2013513755 A JP2013513755 A JP 2013513755A JP 5986072 B2 JP5986072 B2 JP 5986072B2
Authority
JP
Japan
Prior art keywords
buprenorphine
implant
pharmaceutical composition
polymer
lactide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013513755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533230A5 (enExample
JP2013533230A (ja
Inventor
リチャード エル ノートン
リチャード エル ノートン
アンドリュー ワトキンス
アンドリュー ワトキンス
ミンシン チョウ
ミンシン チョウ
Original Assignee
インディヴィオ ユーケー リミテッド
インディヴィオ ユーケー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5986072(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by インディヴィオ ユーケー リミテッド, インディヴィオ ユーケー リミテッド filed Critical インディヴィオ ユーケー リミテッド
Publication of JP2013533230A publication Critical patent/JP2013533230A/ja
Publication of JP2013533230A5 publication Critical patent/JP2013533230A5/ja
Application granted granted Critical
Publication of JP5986072B2 publication Critical patent/JP5986072B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013513755A 2010-06-08 2011-06-06 組成物 Expired - Fee Related JP5986072B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1009549.5 2010-06-08
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
PCT/GB2011/051057 WO2011154724A2 (en) 2010-06-08 2011-06-06 Compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016110259A Division JP6251774B2 (ja) 2010-06-08 2016-06-01 組成物

Publications (3)

Publication Number Publication Date
JP2013533230A JP2013533230A (ja) 2013-08-22
JP2013533230A5 JP2013533230A5 (enExample) 2014-07-24
JP5986072B2 true JP5986072B2 (ja) 2016-09-06

Family

ID=42471306

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013513755A Expired - Fee Related JP5986072B2 (ja) 2010-06-08 2011-06-06 組成物
JP2016110259A Active JP6251774B2 (ja) 2010-06-08 2016-06-01 組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016110259A Active JP6251774B2 (ja) 2010-06-08 2016-06-01 組成物

Country Status (32)

Country Link
US (1) US8921387B2 (enExample)
EP (3) EP3360538B1 (enExample)
JP (2) JP5986072B2 (enExample)
KR (1) KR101865689B1 (enExample)
CN (1) CN103079544B (enExample)
AU (1) AU2011263478B2 (enExample)
BR (1) BR112012031290A2 (enExample)
CA (1) CA2801676C (enExample)
CL (1) CL2012003462A1 (enExample)
CO (1) CO6670529A2 (enExample)
CY (1) CY1120761T1 (enExample)
DK (2) DK3360538T3 (enExample)
ES (2) ES2656938T3 (enExample)
FI (1) FI3360538T3 (enExample)
GB (2) GB2481018B (enExample)
HR (1) HRP20180118T1 (enExample)
HU (1) HUE038275T2 (enExample)
IL (2) IL223488A (enExample)
LT (1) LT2579874T (enExample)
MX (1) MX339209B (enExample)
MY (1) MY171625A (enExample)
NO (1) NO2579874T3 (enExample)
NZ (1) NZ604026A (enExample)
PL (1) PL2579874T3 (enExample)
PT (1) PT2579874T (enExample)
RS (1) RS56820B1 (enExample)
RU (1) RU2607498C2 (enExample)
SG (1) SG186200A1 (enExample)
SI (1) SI2579874T1 (enExample)
SM (1) SMT201800038T1 (enExample)
WO (1) WO2011154724A2 (enExample)
ZA (1) ZA201209233B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2013126552A1 (en) * 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
ES2716570T3 (es) 2012-04-17 2019-06-13 Purdue Pharma Lp Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
ES2837803T3 (es) * 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
EP2931253A1 (en) * 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9592227B2 (en) * 2013-03-15 2017-03-14 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
JP6723162B2 (ja) * 2014-04-21 2020-07-15 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ポリオルトエステルおよび有機酸添加剤の組成物
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
CN106535886A (zh) 2014-04-21 2017-03-22 赫伦治疗有限公司 长效聚合物输送系统
AU2015253417B2 (en) 2014-04-28 2020-02-20 Dimerx, Inc. Pharmaceutically active dimers linked through phenolic hydroxyl groups
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations
US20160128997A1 (en) * 2014-11-07 2016-05-12 Indivior Uk Limited Sustained-release buprenorphine formulations
US10786515B2 (en) 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
PL3512518T3 (pl) * 2016-09-13 2023-03-27 Alar Pharmaceuticals Inc. Preparaty buprenorfiny o przedłużonym uwalnianiu
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
NZ760033A (en) 2017-06-16 2023-02-24 Indivior Uk Ltd Methods to treat opioid use disorder
WO2019144079A1 (en) 2018-01-22 2019-07-25 Yuhua Li Pharmaceutical composition for sustained release delivery of buprenorphine
TWI838372B (zh) 2018-05-11 2024-04-11 昱展新藥生技股份有限公司 丁基原啡因衍生物之長效注射劑型及結晶型
WO2020077235A1 (en) 2018-10-11 2020-04-16 Indivior Uk Limited Buprenorphine to treat respiratory depression
US12403291B2 (en) * 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CN118831057A (zh) * 2023-04-25 2024-10-25 深圳善康医药科技股份有限公司 丁丙诺啡植入剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
US7368126B2 (en) * 2002-11-06 2008-05-06 Guohua Chen Controlled release depot formulations
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
EP1824460B1 (en) * 2004-11-10 2014-12-24 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
EP3202814B1 (en) 2007-02-15 2019-10-16 Tolmar Therapeutics, Inc. Low burst poly-(lactide/glycolide) and methods to produce polymers
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
GB201009549D0 (en) 2010-07-21
KR20130135026A (ko) 2013-12-10
GB2513267B (en) 2015-03-18
RU2012157244A (ru) 2014-07-20
CO6670529A2 (es) 2013-05-15
BR112012031290A2 (pt) 2016-11-01
SI2579874T1 (en) 2018-03-30
MX2012014335A (es) 2013-03-05
SMT201800038T1 (it) 2018-03-08
GB2513267A (en) 2014-10-22
CA2801676A1 (en) 2011-12-15
AU2011263478B2 (en) 2015-01-22
WO2011154724A9 (en) 2012-08-16
IL254417A0 (en) 2017-11-30
EP3360538A1 (en) 2018-08-15
CY1120761T1 (el) 2019-12-11
GB2481018A (en) 2011-12-14
ZA201209233B (en) 2014-04-30
CL2012003462A1 (es) 2013-04-01
IL223488A (en) 2017-10-31
LT2579874T (lt) 2018-02-12
WO2011154724A2 (en) 2011-12-15
JP2016155865A (ja) 2016-09-01
JP6251774B2 (ja) 2017-12-20
EP2579874B1 (en) 2018-01-10
NZ604026A (en) 2015-01-30
PL2579874T3 (pl) 2018-05-30
MX339209B (es) 2016-04-15
US8921387B2 (en) 2014-12-30
PT2579874T (pt) 2018-01-29
EP3360538B1 (en) 2023-02-15
HUE038275T2 (hu) 2018-10-29
AU2011263478A1 (en) 2013-01-10
ES2939612T3 (es) 2023-04-25
WO2011154724A3 (en) 2012-07-12
DK2579874T3 (da) 2018-01-29
JP2013533230A (ja) 2013-08-22
US20130210853A1 (en) 2013-08-15
HRP20180118T1 (hr) 2018-03-09
EP4218720A1 (en) 2023-08-02
RS56820B1 (sr) 2018-04-30
RU2607498C2 (ru) 2017-01-10
NO2579874T3 (enExample) 2018-06-09
CA2801676C (en) 2018-08-07
EP2579874A2 (en) 2013-04-17
ES2656938T3 (es) 2018-03-01
GB201413064D0 (en) 2014-09-03
MY171625A (en) 2019-10-21
DK3360538T3 (da) 2023-03-06
CN103079544A (zh) 2013-05-01
CN103079544B (zh) 2017-06-09
KR101865689B1 (ko) 2018-06-08
FI3360538T3 (fi) 2023-03-22
SG186200A1 (en) 2013-01-30
GB2481018B (en) 2015-03-18

Similar Documents

Publication Publication Date Title
JP6251774B2 (ja) 組成物
US10592168B1 (en) Injectable flowable composition comprising buprenorphine
US8975270B2 (en) Injectable flowable composition comprising buprenorphine
AU2008262545B2 (en) Sustained delivery formulations of risperidone compounds
HK40097172A (en) Injectable flowable composition comprising buprenorphine
HK1184056B (en) Injectable flowable composition comprising buprenorphine
HK1184056A (en) Injectable flowable composition comprising buprenorphine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150803

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160601

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160804

R150 Certificate of patent or registration of utility model

Ref document number: 5986072

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees